Oramed Pharmaceuticals (NASDAQ:ORMP) Cut to Sell at StockNews.com

StockNews.com downgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a hold rating to a sell rating in a research report released on Wednesday morning.

Oramed Pharmaceuticals Trading Down 3.2 %

Shares of ORMP opened at $2.15 on Wednesday. The company’s fifty day simple moving average is $2.33 and its 200 day simple moving average is $2.36. Oramed Pharmaceuticals has a 1-year low of $2.00 and a 1-year high of $3.67. The company has a market cap of $86.67 million, a price-to-earnings ratio of 19.55 and a beta of 1.66.

Institutional Investors Weigh In On Oramed Pharmaceuticals

Several hedge funds have recently bought and sold shares of ORMP. Boothbay Fund Management LLC raised its stake in Oramed Pharmaceuticals by 2.0% in the fourth quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company’s stock valued at $2,045,000 after buying an additional 16,857 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Oramed Pharmaceuticals by 143.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company’s stock worth $288,000 after acquiring an additional 70,190 shares during the last quarter. BML Capital Management LLC raised its stake in Oramed Pharmaceuticals by 20.9% in the 4th quarter. BML Capital Management LLC now owns 2,643,907 shares of the biotechnology company’s stock valued at $6,398,000 after acquiring an additional 457,716 shares during the period. World Equity Group Inc. acquired a new stake in Oramed Pharmaceuticals during the 4th quarter valued at $48,000. Finally, Peapod Lane Capital LLC bought a new position in Oramed Pharmaceuticals during the fourth quarter worth $550,000. 12.73% of the stock is currently owned by institutional investors and hedge funds.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.